(Q37846178)

24 August 2017

title

Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis (English)

1 reference

hereditary hemorrhagic telangiectasia

24 August 2017

main subject

0 references

1 reference

1 reference

Tom T Karnezis

1

1 reference

24 August 2017

Terence M Davidson

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

16 December 2010

1 reference

24 August 2017

1 reference

24 August 2017

volume

121

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

636-638

1 reference

Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

An epistaxis severity score for hereditary hemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

Extracellular control of TGFbeta signalling in vascular development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

Bevacizumab in hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FLARY.21415

21 January 2018

Identifiers

DOI

10.1002/LARY.21415

1 reference

24 August 2017

1 reference